Globus Medical (GMED) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Globus Medical (GMED) PT Raised to $30 at BofA/Merrill Lynch Following Q4, Branch Deal
February 26, 2015 8:37 AM ESTBofA/Merrill Lynch analyst Bob Hopkins reiterated a Buy rating and boosted his price target on Globus Medical (NYSE: GMED) to $30.00 (from $26.00) following Q4 results and the acquisition of Branch.
Hopkins calls Branch a controversial but accretive deal. He also said guidance seems... More



